Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia Biosciences GIPR antagonist
- Development stage
- Preclinical
- Lead developer
- Ambrosia Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ambrosia Biosciences is developing an orally bioavailable small molecule antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) for the treatment of obesity and metabolic disorders. The program focuses on blocking GIPR signaling, a strategy hypothesized to enhance weight loss and improve metabolic parameters, particularly when used in combination with GLP-1 receptor agonists. By utilizing a small molecule modality, the company aims to provide a more convenient alternative to injectable peptide-based incretin therapies. The program is currently in the discovery and preclinical phase, with potential applications in both active weight loss and weight maintenance.
- Other names
- GIPR antagonist (Ambrosia Biosciences)
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on Ambrosia Biosciences GIPR antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambrosia Biosciences GIPR antagonist.